Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (NYSE: VEEV) announces a growing adoption of its Veeva Vault CDMS for clinical data management by numerous biotechs and a top 20 pharmaceutical company. Vault CDMS has been utilized in over 100 trials across various phases and therapeutic areas, enabling faster study initiation. The platform facilitates the creation of study databases in under four weeks and allows for mid-study amendments without downtime. Notable companies like Eli Lilly and Alcon are leveraging Vault CDMS for enhanced data management efficiency.
Veeva Systems (NYSE: VEEV) has launched two applications on the Veeva Clinical Network to streamline clinical trial processes. Veeva Site Connect enables automated information sharing between sponsors and clinical sites, enhancing efficiency in document exchange and site engagement. Veeva eConsent digitizes the patient consent process, improving transparency and compliance. Both solutions aim to accelerate patient-centric trials. The launch responds to growing needs for paperless solutions in the industry and is part of Veeva's commitment to innovation.
Veeva Systems (NYSE: VEEV) recently launched two applications on the Veeva Clinical Network aimed at optimizing clinical trials: Veeva Site Connect and Veeva eConsent. Veeva Site Connect automates information sharing between sponsors and clinical sites, enhancing efficiency in key processes like document exchange. Veeva eConsent digitizes the patient consent process, improving compliance and patient experience. Both solutions are designed to accelerate the transition to paperless, patient-centric trials. Early adopters include major pharmaceutical and medical device companies.
Summary not available.
Summary not available.
Veeva Systems (NYSE: VEEV) announced that Amy Abernethy, MD, PhD, principal deputy commissioner of the FDA, will keynote the 2020 Veeva R&D and Quality Summit Online. The event, scheduled for Oct. 13-14, 2020, will focus on advancing drug development through innovative data and technology solutions. It includes over 100 live and on-demand sessions featuring key players from the pharmaceutical and biotech sectors sharing strategies for efficient clinical and quality processes. The summit is anticipated to attract over 3,000 professionals from the life sciences industry.
Veeva Systems (NYSE: VEEV) announces that Biotest, a German biopharmaceutical company, has adopted Veeva Vault eTMF to enhance oversight and visibility in its European clinical trials. This implementation allows Biotest to manage trial documents in real-time, ensuring constant inspection readiness and accelerating study execution. Veeva Vault eTMF offers advanced reporting and insights, facilitating collaboration among trial sponsors and participants. The initiative underscores Veeva's role in modernizing clinical operations and improving trial efficiency.